Document-based workflows can consume plenty of your time and effort, no matter if you do them regularly or only sometimes. It doesn’t have to be. In reality, it’s so easy to inject your workflows with extra productivity and structure if you engage the proper solution - DocHub. Sophisticated enough to tackle any document-connected task, our software lets you alter text, images, comments, collaborate on documents with other parties, produce fillable forms from scratch or web templates, and digitally sign them. We even safeguard your information with industry-leading security and data protection certifications.
You can access DocHub tools from any location or system. Enjoy spending more time on creative and strategic work, and forget about tiresome editing. Give DocHub a try right now and watch your Technology Assessment workflow transform!
in Europe each country has his own system for reimbursement and pricing of new agent and the system depends on the GDP of the country of the healthcare system and of course of the healthcare priorities so we are not speaking of the process of market access we are just speaking of the evaluation how can we assess the interest value of a new agent and of course each countrys as is own solution depending on these own resources but there are two main system the first one in based on clinical evaluation alone especially in Germany you compare a new agent to the existing drug and you define the added value and then there is a discussion with the pharmaceutical company to find the fair price on the other hand there are countries in which the assessment in base on health economic evaluation and especially on cost utility ratio this is usually a different ratio between the incremental cost and the incremental benefits and its in euro or pound per quali quali is a quality adjusted life here so
